Naloxegol Health Outcome Post Authorisation Safety Study

Status Terminated

Clinical Trial Summary

This post-authorization observational safety study (PASS) monitors clinically important identified and potential risks within a cohort of patients treated with naloxegol, including the occurrence of bowel perforation, acute myocardial infarction (MI), stroke, cardiovascular (CV)-specific mortality, all-cause mortality, hypertension, opioid withdrawal, abdominal pain, diarrhea, syncope, and change in pain severity. This study is part of a broader post-marketing commitment to augment routine evaluation of the safety profile of naloxegol in clinical practice.

Clinical Trial Description

The overall research goal for this study is to provide additional data to characterize the safety of naloxegol in the indicated population, grouped by cancer or non-cancer, and within at-risk vulnerable non-cancer populations identified in the naloxegol risk management plan (RMP) by describing type and frequency of identified and potential risks (including bowel perforation, acute MI, stroke, CV-specific mortality, all-cause mortality, hypertension, opioid withdrawal, abdominal pain, diarrhea, syncope, and change in pain severity) in patients ≥18 years of age who were treated with opioids chronically and subsequently treated with naloxegol in routine post-authorization use. The primary objective of the study is to assess the incidence risk of bowel perforation, acute MI, stroke, all-cause mortality, and hypertension in patients treated with naloxegol (Naloxegol Inception Cohort, (NIC)), grouped by cancer or non cancer, a Concurrent Reference Cohort (CRC) by cancer or non-cancer, and by pre-specified non-cancer sub-populations that include patients aged ≥65 years, pregnant patients, patients with prior CV, patients with prior renal or hepatic impairment, patients with concurrent methadone use, and patients with concurrent use of cytochrome P450 (CYP) 3A inhibitors/inducer or P-glycoprotein (Pgp) modulators. An exploratory objective of the study is to assess the incidence risk of CV-specific mortality, opioid withdrawal, abdominal pain, diarrhea, syncope, and change in pain severity in patients treated with naloxegol (NIC) grouped by cancer and non cancer, a CRC grouped by cancer or non cancer, and by pre-specified non-cancer sub-populations that include patients aged ≥65 years, pregnant patients, patients with prior cardiovascular risk, patients with prior renal or hepatic impairment, patients with concurrent methadone use, and patients with concurrent use of CYP3A inhibitors/inducer or Pgp modulators. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02813369
Study type	Observational
Source	Kyowa Kirin Pharmaceutical Development Ltd
Contact
Status	Terminated
Phase
Start date	September 2016
Completion date	November 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01957046` - A Single-arm, Study to Assess the Effect and Tolerability of Standardised Laxative Therapy (SLT) for the Reversal of Opioid-induced Constipation (OIC).	Phase 4
Completed	`NCT01401985` - A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC)	Phase 2
Completed	`NCT00984334` - Naloxone SR Capsules in Patients With Opioid Induced Constipation	Phase 2
Completed	`NCT01207427` - Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain	Phase 2
Completed	`NCT01459926` - A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation	Phase 2
Terminated	`NCT01117051` - Prucalopride Effects on Subjects With Chronic Non-cancer Pain Suffering From Opioid Induced Constipation	Phase 3
Completed	`NCT03060512` - To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation	Phase 4
Completed	`NCT01109511` - A Comparison of Oxycodone/Naloxone and Oxycodone After Laparoscopic Hysterectomy	Phase 4
Active, not recruiting	`NCT02813356` - Naloxegol US PMR CV Safety.
Completed	`NCT01812733` - Non-interventional Study Comparing Targiniq and Oxycodone/Laxatives	N/A
Completed	`NCT01623609` - Open Label, Healthy Volunteers, Bioequivalence Study With Naloxegol	Phase 1
Completed	`NCT02813148` - Naloxegol Drug Utilization Post Authorisation Safety Study
Completed	`NCT01443403` - A Study of S-297995 for the Treatment of Opioid-Induced Constipation in Subjects With Non-Malignant Chronic Pain Receiving Opioid Therapy	Phase 2
Completed	`NCT03638440` - Real World Observational Study of Naloxegol for Patients With Cancer Pain Diagnosed With OIC.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.